Guardant Health, Inc. (NASDAQ:GH) Receives Average Recommendation of "Moderate Buy" from Analysts

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $37.70.

A number of research analysts have issued reports on GH shares. JPMorgan Chase & Co. decreased their target price on shares of Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Craig Hallum assumed coverage on shares of Guardant Health in a research report on Wednesday, April 24th. They set a "buy" rating and a $28.00 price target on the stock. Piper Sandler cut their target price on shares of Guardant Health from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, February 26th. The Goldman Sachs Group lowered their price target on shares of Guardant Health from $32.00 to $28.00 and set a "buy" rating for the company in a report on Monday, April 15th. Finally, Guggenheim reiterated a "neutral" rating on shares of Guardant Health in a research note on Friday, April 5th.

Insider Buying and Selling

In related news, insider Kumud Kalia purchased 2,187 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the acquisition, the insider now owns 12,722 shares of the company's stock, valued at approximately $226,706.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP boosted its stake in Guardant Health by 269.7% in the 1st quarter. GSA Capital Partners LLP now owns 31,291 shares of the company's stock worth $646,000 after purchasing an additional 22,828 shares during the period. Jennison Associates LLC boosted its position in shares of Guardant Health by 2.0% in the first quarter. Jennison Associates LLC now owns 489,657 shares of the company's stock valued at $10,102,000 after acquiring an additional 9,811 shares during the period. Oak Ridge Investments LLC grew its stake in Guardant Health by 8.5% during the first quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company's stock valued at $382,000 after acquiring an additional 1,451 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Guardant Health by 0.9% during the 1st quarter. Baillie Gifford & Co. now owns 6,232,104 shares of the company's stock worth $128,568,000 after acquiring an additional 53,292 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Guardant Health in the 1st quarter worth approximately $273,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Performance

Shares of GH stock traded up $0.30 on Friday, reaching $18.88. The stock had a trading volume of 1,121,543 shares, compared to its average volume of 1,688,861. The company has a quick ratio of 6.24, a current ratio of 6.54 and a debt-to-equity ratio of 7.18. The firm's 50-day moving average is $18.39 and its two-hundred day moving average is $22.50. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -4.41 and a beta of 0.92. Guardant Health has a 12 month low of $15.81 and a 12 month high of $41.06.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The company had revenue of $155.05 million during the quarter, compared to the consensus estimate of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. On average, research analysts expect that Guardant Health will post -3.49 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.